drugset / Trial / NCT02919995

A Study of RPL554 in Patients With Cystic Fibrosis

NCT02919995

RandomizedCrossoverTriple-blindTreatment

Summary

This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.

Timeline

Start
2017-02-08
Primary completion
2017-11-03
Completion
2017-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ensifentrine Unknown 1.5 mg Inhaled
Subject Ensifentrine Unknown 6 mg Inhaled

Indications